Related Experiment Video
Updated: Mar 17, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT
Priscila Da Silva Figueiredo Celestino Gomes1,2, Isaure Chauvot De Beauchêne1, Nicolas Panel1
1Laboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS Cachan, CNRS, Université, Paris-Saclay, 94235 Cachan, France.
Abstract:
The receptors tyrosine kinases (RTKs) for the colony stimulating factor-1, CSF-1R, and for the stem cell factor, SCFR or KIT, are important mediators of signal transduction. The abnormal function of these receptors, promoted by gain-of-function mutations, leads to their constitutive activation, associated with cancer or other proliferative diseases. A secondary effect of the mutations is the alteration of receptors' sensitivity to tyrosine kinase inhibitors, compromising effectiveness of these molecules in clinical treatment. In particular, the mutation V560G in KIT increases its sensitivity to Imatinib, while the D816V in KIT, and D802V in CSF-1R, triggers resistance to the drug. We analyzed the Imatinib binding affinity to the native and mutated KIT (mutations V560G, S628N and D816V) and CSF-1R (mutation D802V) by using molecular dynamics simulations and energy calculations of Imatinib•target complexes. Further, we evaluated the sensitivity of the studied KIT receptors to Imatinib by measuring the inhibition of KIT phosphorylation. Our study showed that (i) the binding free energy of Imatinib to the targets is highly correlated with their experimentally measured sensitivity; (ii) the electrostatic interactions are a decisive factor affecting the binding energy; (iii) the most deleterious impact to the Imatinib sensitivity is promoted by D802V (CSF-1R) and D816V (KIT) mutations; (iv) the role of the juxtamembrane region, JMR, in the imatinib binding is accessory. These findings contribute to a better description of the mutation-induced effects alternating the targets sensitivity to Imatinib.
Insights
Tyrosine kinase inhibitors like Imatinib can be affected by mutations in KIT and CSF-1R receptors. Specific mutations, such as D802V in CSF-1R and D816V in KIT, cause resistance to Imatinib treatment.
Area of Science:
- Molecular biology
- Biochemistry
- Pharmacology
Background:
- Receptor tyrosine kinases (RTKs), including CSF-1R and KIT, are crucial for signal transduction.
- Gain-of-function mutations in RTKs can lead to constitutive activation, driving cancer and proliferative diseases.
- Mutations alter RTK sensitivity to tyrosine kinase inhibitors, impacting therapeutic efficacy.
Purpose of the Study:
- To investigate the impact of specific KIT and CSF-1R mutations on Imatinib binding affinity and drug sensitivity.
- To elucidate the molecular mechanisms underlying mutation-induced alterations in drug response.
Main Methods:
- Molecular dynamics simulations and energy calculations of Imatinib•target complexes.
- Analysis of Imatinib binding free energy to native and mutated KIT and CSF-1R.
- Experimental measurement of KIT receptor phosphorylation inhibition to assess drug sensitivity.
Main Results:
- A strong correlation exists between calculated binding free energy and experimentally determined Imatinib sensitivity.
- Electrostatic interactions significantly influence Imatinib binding energy to RTKs.
- CSF-1R D802V and KIT D816V mutations most severely decrease Imatinib sensitivity.
- The juxtamembrane region (JMR) plays a minor role in Imatinib binding.
Conclusions:
- Binding free energy calculations accurately predict drug sensitivity changes due to RTK mutations.
- Electrostatic forces are key determinants of Imatinib efficacy against mutated RTKs.
- Understanding these mutation-drug interactions can inform the development of more effective cancer therapies.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015